BRAFV600E mutant colorectal cancer cells mediate local immunosuppressive microenvironment through exosomal long noncoding RNAs

Table 1 Relationship between BRAF^V600E mutation and clinicopathological parameters in colorectal cancer

Variable	Cases (%)	BRAFV600E mutation		P value
		Yes (%)	No (%)
Gender
Male	18 (60)	6 (60)	12 (60)	0.326
Female	12 (40)	4 (40)	8 (40)
Age (yr)
≥ 65	10 (33.3)	4 (40)	6 (30)	0.440
< 65	20 (66.7)	6 (60)	14 (70)
Location
Right colon	9 (30)	2 (20)	7 (35)	0.345
Left colon	9 (30)	5 (50)	4 (20)
Rectum	12 (40)	3 (30)	9 (45)
Mucous tissue
Positive	6 (20)	1 (10)	5 (25)	0.326
Negative	24 (80)	9 (90)	15 (75)
Differentiated degree
High/moderate differentiation	20 (66.7)	3 (30)	17 (85)	0.005a
Poor differentiation	10 (33.3)	7 (70)	3 (15)
T stage
T2	4 (13.3)	0	4 (20)	0.211
T3	3 (10)	2 (20)	1 (5)
T4	23 (76.7)	8 (80)	15 (75)
TNM stage
I + II	13 (43.3)	2 (20)	11 (55)	0.074
III + IV	17 (56.7)	8 (80)	9 (45)
Lymph node
Positive	17 (56.7)	8 (80)	9 (45)	0.074
Negative	13 (43.3)	2 (20)	11 (55)
Nerve invasion
Positive	7 (23.3)	4 (40)	3 (15)	0.143
Negative	23 (76.7)	6 (60)	17 (85)
Vessel carcinoma embolus
Positive	3 (10)	1 (10)	2 (10)	0.652
Negative	27 (90)	9 (90)	18 (90)
CA19-9 (U/mL)
High	12 (40)	7 (70)	5 (25)	0.024a
Normal	18 (60)	3 (30)	15 (75)
CEA (ng/mL)
High	11 (36.7)	3 (30)	8 (40)	0.452
Normal	19 (63.3)	7 (70)	12 (60)
PLT count (× 109/L)
High	12 (40)	5 (50)	7 (35)	0.344
Normal	18 (60)	5 (50)	13 (65)

^aP < 0.05.

PLT: Platelets; CEA: Carcinoembryonic antigen; CA19-9: Carbohydrate antigen 19-9.